Ultragenyx
Price & Volume
Stats
See moreOpen | $50.78 |
Previous Close | $50.99 |
Day Range | $49.94-$50.93 |
52W Range | $34.06-$60.37 |
Market Cap | $4.6B |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $481.3M |
Revenue Growth (YoY) | 35.7% |
Gross Profit (12 Mos) | -$370.7M |
Diluted EPS | -$7.21 |
News
See moreYahoo Finance • 5 months ago
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Yahoo Finance • 5 months ago
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
Yahoo Finance • 6 months ago
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Yahoo Finance • 8 months ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
About
CEO | Dr. Emil D. Kakkis M.D., Ph.D. |
CFO | Mr. Howard Horn |
Address | 60 Leveroni Court, Novato, CA, United States, 94949 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 1,276 |
